Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Routine venoarterial extracorporeal membrane oxygenation for acute myocardial infarction-related cardiogenic shock: what we know and don't know.

Intensive care medicine·2024

Same author

Ventricular septal defect complicating acute myocardial infarction: diagnosis and management. A Clinical Consensus Statement of the Association for Acute CardioVascular Care (ACVC) of the ESC, the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC and the ESC Working Group on Cardiovascular Surgery.

European heart journal·2024

Same author

Impact of Blood Pressure Targets in Patients With Heart Failure Undergoing Postresuscitation Care: A Subgroup Analysis From a Randomized Controlled Trial.

Circulation. Heart failure·2024

Same author

Future for cardiogenic shock research.

Current opinion in critical care·2024

Same author

Vasodilators for Acute Heart Failure - A Systematic Review with Meta-Analysis.

NEJM evidence·2024

Same author

Biomarker patterns in patients with cardiogenic shock versus septic shock.

International journal of cardiology. Heart & vasculature·2024

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

[Percutaneous assist device during acute heart failure].

Matias Greve Lindholm¹, Thomas Engstrøm, Kristian Wachtell

¹Rigshospitalet, Kardiologisk og Thoraxkirurgisk klinik, København Ø. matiasgl@rh.dk

Ugeskrift for Laeger

|October 24, 2007

Summary

Newer left ventricular assist devices offer improved treatment for heart failure patients. The Impella Recover LP 2.5 is a safe, smaller option that increases blood flow and reduces metabolic demand.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Experiment Videos

Last Updated: Jul 10, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Area of Science:

Cardiology
Biomedical Engineering

Background:

International guidelines support intraaortic balloon pumps (IABP) for left ventricular assist.
Emerging alternative assist devices aim to enhance heart failure treatment.
Understanding these devices is crucial for effective patient management.

Purpose of the Study:

To review current left ventricular assist devices beyond IABP.
To highlight the benefits and safety of newer technologies like the Impella Recover LP 2.5.

Main Methods:

Review of existing literature on left ventricular assist devices.
Analysis of technological advancements in smaller assist devices.
Evaluation of the Impella Recover LP 2.5's performance and safety profile.

Main Results:

The TandemHeart device increases blood flow and reduces metabolic demand but has reported complications.
Technological progress has led to smaller, more advanced assist devices.
The Impella Recover LP 2.5 demonstrated safety and achieved a flow increase of 2.5 L/min, decreasing metabolic demands.

Conclusions:

The Impella Recover LP 2.5 represents a safe and effective advancement in left ventricular assist devices.
Smaller, technologically improved assist devices can enhance the treatment of heart failure patients.